AVELOX
LOE ApproachingNDAORALTABLET
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
AVELOX by Bayer is [see clinical pharmacology ()]. Approved for administration (), use in specific populations ()], acute bacterial sinusitis caused by streptococcus pneumoniae and 25 more indications. First approved in 1999.
Drug data last refreshed 22h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVELOX (moxifloxacin) is an oral fluoroquinolone antibiotic approved in 1999 for treating respiratory, skin, and intra-abdominal infections caused by susceptible gram-positive and gram-negative bacteria. It is indicated for acute bacterial sinusitis, community-acquired pneumonia (including multi-drug resistant strains), acute exacerbation of chronic bronchitis, complicated skin/skin structure infections, and complicated intra-abdominal infections. The drug works through bacterial DNA gyrase and topoisomerase IV inhibition, typical of the fluoroquinolone class.
LOE Approaching
Product is in late-cycle phase with limited growth prospects; commercial teams likely focusing on cost management and narrow specialist segments.
Mechanism of Action
[see Clinical Pharmacology ()].
Worked on AVELOX at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.